We may be underestimating the underlying inteirm trial data that we know nothing about. here is my thesis: the data was very compelling to DSMC and they realize that the 149 of the 195 were admitted prior to July 16. think about that...lot more ignorance at that time on standard of care options and therapies. that might be why they subtly say continue but underneath the hood = "wow"

In other words, probably if you did some math like this//////
Keep the ratio of placebo deaths to leronlimab deaths the same.
But increase the total number of patients in the s/c trial to 300 (or maybe just 293), In which case, you would achieve Statistical Significance.